Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Biovian
Biovian
Activities:
Manufacturing
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Biovian and 3P Biopharmaceuticals, two leading biologics CDMOs, announce their combination to establish a new pan-European leader in their field
Manufacturing
Biovian announces over €50 million investment in Finnish viral vector facility
The additional space complements Biovian’s existing manufacturing facilities in the area and will enable Biovian to undertake larger-scale viral vector as well as microbial protein projects
Manufacturing
Lokon and Biovian sign manufacturing agreement for cancer therapy
The agreement covers the development and manufacturing of the viral vector LOAd703 at Biovian’s facility in Turku, Finland
Manufacturing
Tenboron and Biovian sign manufacturing agreement for cancer therapy
The agreement covers technical transfer, analytical method validation and GMP manufacturing of boron carriers at Biovian’s facility in Turku, Finland
Biovian appoints Head of Global Business Development
Dr Magnus Gustafsson has been chosend to runt he business and marketing team
Subscribe now